Last reviewed · How we verify
Dalbavancin via Intravenous Administration
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms, Staphylococcus aureus bacteremia including endocarditis.
At a glance
| Generic name | Dalbavancin via Intravenous Administration |
|---|---|
| Sponsor | University of Colorado, Denver |
| Drug class | Lipoglycopeptide antibiotic |
| Target | D-Ala-D-Ala peptidoglycan precursors |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Dalbavancin binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, preventing cross-linking and disrupting cell wall integrity. This leads to bacterial cell lysis and death. It has enhanced activity against gram-positive bacteria compared to earlier glycopeptides due to its improved tissue penetration and longer half-life.
Approved indications
- Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms
- Staphylococcus aureus bacteremia including endocarditis
Common side effects
- Infusion-related reactions
- Headache
- Nausea
- Diarrhea
- Vulvovaginal mycotic infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: